US Large-Cap Pharma/Healthcare
Large-cap healthcare ecosystem: GLP-1 revolution, oncology/immunotherapy, vaccine franchises, and integrated health insurers. Structurally defensive sector offsetting drug-price and patent-cliff risk via M&A and pipelines.
Investment Confidence
Theme Analysis
Key Drivers
- GLP-1 obesity/diabetes megatrend
- Oncology/immunotherapy pipelines
- Aging-population TAM expansion
- Dividend + buyback programs
Risk Factors
- IRA drug-price negotiation expansion
- Patent cliffs (Humira, Keytruda)
- PBM/MA regulation
- Rate sensitivity
Catalysts
Related Investment Ideas
5UnitedHealth — #1 US Health Insurer, MA Pressure vs Optum Growth
#1 US health insurer (UnitedHealthcare) + healthcare services platform (Optum). Near-term pressure from 2026 Medicare Advantage cost trend + membership dip; Optum Health/Insight/Rx provide structural growth offset. Q1 2026 earnings due 4/21.
Johnson & Johnson — Q1 2026 Beat + Guidance Raise
Q1 2026 (4/14): revenue $24.1B (+9.9%), adj EPS $2.70 (beat $2.66 consensus). Pharma $15.4B (+11.2%, Darzalex/Tremfya led), Med Devices $8.6B (+7.7%). FY2026 guidance raised to $100.8B revenue / $11.55 adj EPS midpoint. Newly launched oral psoriasis drug Icotyde shows positive early uptake.
Pfizer — Post-COVID Normalization, Seagen/Oncology Growth Test
Post-COVID / Paxlovid normalization. Seagen acquisition ($43B) bulks up oncology. FY2026 guidance: revenue $59.5–62.5B, adj EPS $2.80–3.00. Q1 earnings due 5/5 (consensus $0.72). High-yielding with 6%+ dividend.
Merck — Keytruda Empire vs 2028 Patent Cliff
Keytruda (immuno-oncology) is a $30B+ flagship. 2028 patent cliff being addressed via M&A and pipeline expansion. Growth in Gardasil (HPV) and animal health. Attractive dividend + stable cash-flow profile.
AbbVie — Post-Humira Era, Skyrizi/Rinvoq Hyper-Growth
Post-Humira pivot successful: Skyrizi (psoriasis) and Rinvoq (rheumatology) each visible on a $20B+ run-rate path. Diversified via neuroscience (Qulipta, Vraylar) and aesthetics (Botox, Juvederm). Dividend aristocrat with $22B+ FCF.